The combination of RAC inhibitors and mTOR inhibitors significantly inhibited MFS growth.[40] Moreover, from an immunomics perspective, sarcomas with complex karyotypes, including MFS, exhibit a tumor microenvironment characterized by a high degree of immune infiltration, which increases the likelihood of response to immunotherapy.[41] The expression levels of immune microenvironment markers, including B7-H3, TGF-β1, and TIM-3, as well as the immune infiltration score, are elevated in MFS. The gene discussed is MTOR; the disease is neoplasm.